DK0923570T3 - Pyridylalken- og pyridylalkynsyreamider som cytostatiske og immunosuppresive midler - Google Patents

Pyridylalken- og pyridylalkynsyreamider som cytostatiske og immunosuppresive midler

Info

Publication number
DK0923570T3
DK0923570T3 DK97928261T DK97928261T DK0923570T3 DK 0923570 T3 DK0923570 T3 DK 0923570T3 DK 97928261 T DK97928261 T DK 97928261T DK 97928261 T DK97928261 T DK 97928261T DK 0923570 T3 DK0923570 T3 DK 0923570T3
Authority
DK
Denmark
Prior art keywords
acid amides
pyridylalkynic
pyridylalkene
cytostatic
immunosuppressive agents
Prior art date
Application number
DK97928261T
Other languages
Danish (da)
English (en)
Inventor
Elfi Biedermann
Max Hasmann
Roland Loeser
Benno Rattel
Friedemann Reiter
Barbara Schein
Klaus Seibel
Klaus Vogt
Original Assignee
Fujisawa Deutschland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Deutschland Gmbh filed Critical Fujisawa Deutschland Gmbh
Application granted granted Critical
Publication of DK0923570T3 publication Critical patent/DK0923570T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56Amides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576Six-membered rings
    • C07F9/59Hydrogenated pyridine rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Catalysts (AREA)
DK97928261T 1996-06-20 1997-06-20 Pyridylalken- og pyridylalkynsyreamider som cytostatiske og immunosuppresive midler DK0923570T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19624659A DE19624659A1 (de) 1996-06-20 1996-06-20 Neue Pyridylalken- und Pyridylalkinsäureamide
PCT/EP1997/003245 WO1997048696A1 (en) 1996-06-20 1997-06-20 Pyridyl alkene- and pyridyl alkine- acid amides as cytostatics and immunosuppressives

Publications (1)

Publication Number Publication Date
DK0923570T3 true DK0923570T3 (da) 2003-01-20

Family

ID=7797501

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97928261T DK0923570T3 (da) 1996-06-20 1997-06-20 Pyridylalken- og pyridylalkynsyreamider som cytostatiske og immunosuppresive midler

Country Status (19)

Country Link
US (3) US7241745B2 (cs)
EP (1) EP0923570B1 (cs)
JP (1) JP4225572B2 (cs)
CN (2) CN1152032C (cs)
AT (1) ATE224888T1 (cs)
AU (1) AU736206B2 (cs)
BR (1) BR9709823B1 (cs)
CA (1) CA2257448C (cs)
CZ (1) CZ291791B6 (cs)
DE (2) DE19624659A1 (cs)
DK (1) DK0923570T3 (cs)
ES (1) ES2179351T3 (cs)
HU (1) HU225715B1 (cs)
IL (1) IL127352A (cs)
PT (1) PT923570E (cs)
RU (1) RU2200734C2 (cs)
TR (1) TR199802651T2 (cs)
WO (1) WO1997048696A1 (cs)
ZA (1) ZA975437B (cs)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19624659A1 (de) * 1996-06-20 1998-01-08 Klinge Co Chem Pharm Fab Neue Pyridylalken- und Pyridylalkinsäureamide
DE19756235A1 (de) * 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab Neue piperidinylsubstituierte Pyridylalkan- alken- und -alkincarbonsäureamide
DE19756261A1 (de) * 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab Neue arylsubstituierte Pyridylalkan-, alken- und alkincarbonsäureamide
DE19756236A1 (de) * 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab Neue piperazinylsubstituierte Pyridylalkan-, alken- und -alkincarbonsäureamide
DE19756212A1 (de) * 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab Neue, mit einem cyclischen Imid substituierte Pyridylalkan-, alken- und -alkincarbonsäureamide
DE19818044A1 (de) * 1998-04-22 1999-10-28 Klinge Co Chem Pharm Fab Verwendung von Vitamin-PP-Verbindungen
ATE280157T1 (de) * 1998-11-17 2004-11-15 Hoffmann La Roche 4-aroyl-piperidin-ccr-3 rezeptor antagonisten iii
EP1031564A1 (en) * 1999-02-26 2000-08-30 Klinge Pharma GmbH Inhibitors of cellular nicotinamide mononucleotide formation and their use in cancer therapy
US6432432B1 (en) 1999-03-05 2002-08-13 Arch Chemicals, Inc. Chemical method of making a suspension, emulsion or dispersion of pyrithione particles
CO5180550A1 (es) 1999-04-19 2002-07-30 Smithkline Beecham Corp Inhibidores de fab i
AR024158A1 (es) 1999-06-01 2002-09-04 Smithkline Beecham Corp Compuestos antibacterianos
US6730684B1 (en) 1999-10-08 2004-05-04 Affinium Pharmaceuticals, Inc. Fab I inhibitors
US6762201B1 (en) 1999-10-08 2004-07-13 Affinium Pharmaceuticals, Inc. Fab I inhibitors
DE60017180T2 (de) 1999-10-08 2005-12-08 Affinium Pharmaceuticals, Inc., Toronto Fab i inhibitoren
US7049310B2 (en) 2001-04-06 2006-05-23 Affinium Pharmaceuticals, Inc. Fab I inhibitors
FR2823975B1 (fr) * 2001-04-27 2003-05-30 Sanofi Synthelabo Nouvelle utilisation de pyridoindolone
EP1348434A1 (en) * 2002-03-27 2003-10-01 Fujisawa Deutschland GmbH Use of pyridyl amides as inhibitors of angiogenesis
ATE374766T1 (de) 2003-01-14 2007-10-15 Arena Pharm Inc 1,2,3-trisubstituierte aryl- und heteroarylderivate als modulatoren des metabolismus zur vorbeugung und behandlung von metabolismus-bedingten krankheiten wie diabetes oder hyperglykämie
EP1768662A2 (en) 2004-06-24 2007-04-04 Novartis Vaccines and Diagnostics, Inc. Small molecule immunopotentiators and assays for their detection
DOP2006000010A (es) 2005-01-10 2006-07-31 Arena Pharm Inc Procedimiento para preparar eteres aromáticos
US20110045065A1 (en) * 2005-07-11 2011-02-24 Ashok Vasantray Vyas Substance having antioxidant, geroprotective and anti-ischemic activity and method for the preparation thereof
US8067457B2 (en) 2005-11-01 2011-11-29 Millennium Pharmaceuticals, Inc. Compounds useful as antagonists of CCR2
WO2007053499A2 (en) 2005-11-01 2007-05-10 Millennium Pharmaceuticals, Inc. Compounds useful as antagonists of ccr2
EP2687533B1 (en) 2006-07-20 2017-07-19 Debiopharm International SA Acrylamide derivatives as FAB I inhibitors
WO2008026018A1 (en) 2006-09-01 2008-03-06 Topotarget Switzerland Sa New method for the treatment of inflammatory diseases
EP3255045A1 (en) 2007-02-16 2017-12-13 Debiopharm International SA Salts, prodrugs and polymorphs of fab i inhibitors
EP2098231A1 (en) 2008-03-05 2009-09-09 Topotarget Switzerland SA Use of NAD formation inhibitors for the treatment of ischemia-reperfusion injury
MX2010014310A (es) 2008-06-24 2011-02-15 Topotarget As Derivados de acido escuarico como inhibidores de la nicotinamida.
AU2009286604B2 (en) 2008-08-29 2015-05-28 Onxeo Dk, Branch Of Onxeo S.A., France Novel urea and thiourea derivatives
CN102421754B (zh) * 2009-05-12 2013-11-27 北京世桥生物制药有限公司 丙烯酰胺类衍生物及其制备药物的用途
CA2768338A1 (en) 2009-07-17 2011-01-20 Topotarget A/S Method for predicting the utility of administering nicotinic acid or a precursor or prodrug thereof to reduce the severity of side-effects of cancer treatment with nicotinamide phosphoribosyltransferase inhibitors
WO2011121055A1 (en) 2010-03-31 2011-10-06 Topotarget A/S Pyridinyl derivatives comprising a cyanoguanidine or squaric acid moiety
IN2013CN02463A (cs) 2010-09-03 2015-08-07 Forma Tm Llc
CN103270023B (zh) 2010-09-03 2016-11-02 福马Tm有限责任公司 作为用于治疗疾病诸如癌症的nampt 抑制剂的4-{[(吡啶-3-基-甲基)氨基羰基]氨基}苯-砜衍生物
CA2810049A1 (en) 2010-09-03 2012-03-08 Forma Tm, Llc Guanidine compounds and compositions for the inhibition of nampt
BR112013008100A2 (pt) 2010-09-22 2016-08-09 Arena Pharm Inc "moduladores do receptor de gpr19 e o tratamento de distúrbios relacionados a eles."
CA2811369C (en) * 2010-09-29 2019-09-03 Intervet International B.V. N-heteroaryl compounds
CN103347860A (zh) 2010-11-15 2013-10-09 Abbvie公司 Nampt抑制剂
RU2013126657A (ru) 2010-11-15 2014-12-27 Эббви Инк. Ингибиторы nampt и rock
AU2011367222B2 (en) * 2011-05-04 2017-04-13 Forma Tm, Llc Novel compounds and compositions for the inhibition of NAMPT
BR112013028877A2 (pt) 2011-05-09 2017-01-31 Forma Tm Llc derivados de piperidina e composições para a inibição de nicotinamida fosforibosiltransferase (nampt)
KR20230042129A (ko) 2011-07-29 2023-03-27 카리오팜 쎄라퓨틱스, 인코포레이티드 하이드라지드 함유 핵 수송 조절인자 및 이의 용도
US9266843B2 (en) 2012-05-09 2016-02-23 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
US9334264B2 (en) 2012-05-11 2016-05-10 Abbvie Inc. NAMPT inhibitors
MX2014013752A (es) 2012-05-11 2014-12-08 Abbvie Inc Inhibidores de nampt.
MX2014013734A (es) 2012-05-11 2015-06-10 Abbvie Inc Inhibidores de nampt.
UY34804A (es) 2012-05-11 2013-12-31 Abbvie Inc Inhibidores del nampt
AU2013279021C1 (en) 2012-06-19 2017-03-16 Debiopharm International Sa Prodrug derivatives of (E)-N-methyl-N-((3-methylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide
WO2014085607A1 (en) * 2012-11-29 2014-06-05 Karyopharm Therapeutics Inc. Substituted 2,3-dihydrobenzofuranyl compounds and uses thereof
WO2014144772A1 (en) 2013-03-15 2014-09-18 Karyopharm Therapeutics Inc. Methods of promoting wound healing using crm1 inhibitors
UA119238C2 (uk) 2013-06-21 2019-05-27 Каріофарм Терапеутікс Інк. Модулятори ядерного транспорту та їх застосування
SG11201510339UA (en) * 2013-07-03 2016-01-28 Karyopharm Therapeutics Inc Substituted benzofuranyl and benzoxazolyl compounds and uses thereof
WO2015042414A1 (en) 2013-09-20 2015-03-26 Karyopharm Therapeutics Inc. Multicyclic compounds and methods of using same
CA2921532A1 (en) * 2013-10-09 2015-04-16 Eli Lilly And Company Novel pyridyloxyacetyl tetrahydroisoquinoline compounds useful as nampt inhibitors
EP3172205A1 (en) 2014-07-23 2017-05-31 Aurigene Discovery Technologies Limited 4,5-dihydroisoxazole derivatives as nampt inhibitors
KR102608259B1 (ko) 2014-08-15 2023-11-29 카리오팜 쎄라퓨틱스, 인코포레이티드 셀리넥소의 다형태
HUE069888T2 (hu) 2015-01-06 2025-04-28 Arena Pharm Inc Vegyületek az S1P1 receptorral összefüggõ állapotok kezelésében történõ alkalmazásra
CN104447484B (zh) * 2015-01-13 2016-06-08 佛山市赛维斯医药科技有限公司 含烷氧苯基和二烯金刚烷结构的化合物、其制备方法和用途
CN104447483B (zh) * 2015-01-13 2016-07-27 佛山市赛维斯医药科技有限公司 含苯胺和二烯金刚烷结构的化合物、其制备方法和用途
CN104447486B (zh) * 2015-01-13 2016-06-01 佛山市赛维斯医药科技有限公司 二烯氟代金刚烷类化合物、其制备方法和用途
KR102883123B1 (ko) 2015-06-22 2025-11-10 아레나 파마슈티칼스, 인크. S1p1 수용체-관련 장애에서의 사용을 위한 (r)-2-(7-(4-시클로펜틸-3-(트리플루오로메틸)벤질옥시)-1,2,3,4-테트라히드로시클로-펜타[b]인돌-3-일)아세트산 (화합물 1)의 결정성 l-아르기닌 염
CN108137563A (zh) 2015-08-18 2018-06-08 卡尔约药物治疗公司 用于治疗癌症的(S,E)-3-(6-氨基吡啶-3-基)-N-((5-(4-(3-氟-3-甲基吡咯烷-l-羰基)苯基)-7-(4-氟苯基)苯并呋喃-2-基)甲基)丙烯酰胺
TWI730985B (zh) * 2015-09-15 2021-06-21 美商艾森伯利生物科學公司 B型肝炎核心蛋白質調節劑
WO2017117447A1 (en) 2015-12-31 2017-07-06 Karyopharm Therapeutics Inc. Multicyclic compounds and uses thereof
EP3397633A1 (en) 2015-12-31 2018-11-07 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
WO2017117535A1 (en) 2015-12-31 2017-07-06 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
HRP20210012T1 (hr) 2016-02-26 2021-03-05 Debiopharm International Sa Lijek za liječenje infekcija dijabetičkog stopala
EP3279192A1 (en) * 2016-08-05 2018-02-07 Centre Hospitalier Universitaire Vaudois (CHUV) Piperidine derivatives for use in the treatment of pancreatic cancer
WO2018086703A1 (en) 2016-11-11 2018-05-17 Bayer Pharma Aktiengesellschaft Dihydropyridazinones substituted with phenylureas
US11602530B2 (en) 2016-11-28 2023-03-14 Biogen Ma Inc. CRM1 inhibitors for treating epilepsy
CN107827897A (zh) * 2017-10-23 2018-03-23 青岛大学 一种手性七元螺环吲哚酮类化合物的合成方法
US20200360531A1 (en) 2018-01-31 2020-11-19 Bayer Aktiengesellschaft Antibody drug conjugates (adcs) with nampt inhibitors
CN108558840B (zh) * 2018-06-04 2020-11-06 上海交通大学 水溶性氮杂α-萘黄酮类化合物及其制备方法和医药用途
CN112601516A (zh) 2018-06-06 2021-04-02 艾尼纳制药公司 治疗与s1p1受体相关的病况的方法
SG11202108591PA (en) 2019-02-14 2021-09-29 Debiopharm Int Sa Afabicin formulation, method for making the same
EA202290048A1 (ru) 2019-06-14 2022-03-10 Дебиофарм Интернэшнл C.A. Лекарственное средство и его применение для лечения бактериальных инфекций, связанных с биопленкой
WO2021013693A1 (en) 2019-07-23 2021-01-28 Bayer Pharma Aktiengesellschaft Antibody drug conjugates (adcs) with nampt inhibitors
PH12022551081A1 (en) 2019-11-06 2024-06-19 Remedy Plan Inc Cancer treatments targeting cancer stem cells
EP4337639A1 (en) 2021-05-13 2024-03-20 Remedy Plan, Inc. Nampt inhibitors and uses thereof

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4283541A (en) 1980-05-27 1981-08-11 Usv Pharmaceutical Corporation Pyridylacyl-hydroxamates
NL8005133A (nl) 1980-09-12 1982-04-01 Duphar Int Res Fenylpiperazinederivaten met antiagressieve werking.
US5326772A (en) 1984-09-28 1994-07-05 Byk Gulden Lomberg Chemische Fabrik Gmbh Diaryl compounds for their use
US4778796A (en) 1985-07-19 1988-10-18 Dainippon Pharmaceutical Co., Ltd. ω-(3-pyridyl)alkenamide derivatives and anti-allergenic pharmaceutical compositions containing same
DE3641822A1 (de) 1986-12-06 1988-06-16 Goedecke Ag Verwendung von dihydrophenylaminosaeurederivaten und diese enthaltende arzneimittel zur immunmodulation und cytostase
JPS63179869A (ja) 1987-01-20 1988-07-23 Dainippon Pharmaceut Co Ltd ピペリジン誘導体
JP2832979B2 (ja) * 1988-02-15 1998-12-09 武田薬品工業株式会社 不飽和カルボン酸アミド誘導体
EP0401256B1 (de) 1988-02-19 1993-05-26 Byk Gulden Lomberg Chemische Fabrik GmbH Optisch reines dexniguldipin und dessen derivate zur behandlung von tumorerkrankungen
EP0343307A1 (en) * 1988-05-26 1989-11-29 Fabrica Espanola De Productos Quimicos Y Farmaceuticos, S.A. 4-Piperidinealkanamine derivatives
IE903196A1 (en) 1989-09-05 1991-03-13 Searle & Co Substituted n-benzylpiperidine amides
US5125957A (en) * 1989-11-01 1992-06-30 Sumitomo Chemical Company, Limited Pyrimidine derivatives
IE903957A1 (en) 1989-11-06 1991-05-08 Sanofi Sa Aromatic amine compounds, their method of preparation and¹pharmaceutical compositions in which they are present
WO1991015485A1 (de) 1990-04-10 1991-10-17 Byk Gulden Lomberg Chemische Fabrik Gmbh Neue pyridinester
EP0524974A1 (de) 1990-04-10 1993-02-03 Byk Gulden Lomberg Chemische Fabrik Gmbh Pyridine als arzneimittel
US5260323A (en) 1990-06-28 1993-11-09 Hoechst Aktiengesellschaft 2,4- and 2,5-substituted pyridine-N-oxides, processes for their preparation and their use
DE4020570A1 (de) 1990-06-28 1992-01-02 Hoechst Ag 2,4- und 2,5-substituierte pyridin-n-oxide, verfahren zu deren herstellung sowie deren verwendung
CA2048110C (en) 1990-07-30 2002-06-25 Muneo Takatani Imidazopyridine derivatives and their use
EP0479601B1 (en) 1990-10-05 1999-12-15 Ajinomoto Co., Inc. Piperidine derivatives and their use as antiarrhythmic agents
FR2676053B1 (fr) 1991-05-03 1993-08-27 Sanofi Elf Nouveaux composes dialkylenepiperidino et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant.
EP0612729B1 (en) 1991-05-10 1997-04-23 Takeda Chemical Industries, Ltd. Pyridine derivatives, their production and use
US5208247A (en) 1991-08-01 1993-05-04 American Cyanamid Company Pyridinium compounds which are useful as antagonists of platelet activating factor
EP0548883A1 (de) 1991-12-24 1993-06-30 Hoechst Aktiengesellschaft Substituierte Pyridin-N-oxide, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Arzneimittel
CA2126976A1 (en) 1991-12-31 1993-07-08 Hisashi Takasugi Oxadiazole derivatives having acetylcholinesterase-inhibitory and muscarinic agonist activity
GB9200535D0 (en) 1992-01-10 1992-02-26 Fujisawa Pharmaceutical Co New compound
FR2686084B1 (fr) 1992-01-10 1995-12-22 Bioprojet Soc Civ Nouveaux derives de l'imidazole, leur preparation et leurs applications therapeutiques.
US5612336A (en) 1992-07-13 1997-03-18 Merck, Sharp & Dohme Ltd. Heterocyclic amide derivatives as tachykinin antagonists
ATE210653T1 (de) 1993-10-15 2001-12-15 Schering Corp Tricyclische sulfonamide-derivate zur inhibierung der g-protein funktion und fur die bekandlung von proliferativen erkrantungen
IL111235A (en) 1993-10-15 2001-03-19 Schering Plough Corp Medicinal preparations for inhibiting protein G activity and for the treatment of malignant diseases, containing tricyclic compounds, some such new compounds and a process for the preparation of some of them
EP0723538B1 (en) 1993-10-15 2001-12-12 Schering Corporation Tricyclic carbamate compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
CA2185448A1 (en) 1994-03-14 1995-09-21 James L. Mulshine Use of lipoxygenase inhibitors as anti-cancer therapeutic and intervention agents
IL117798A (en) 1995-04-07 2001-11-25 Schering Plough Corp Tricyclic compounds useful for inhibiting the function of protein - G and for the treatment of malignant diseases, and pharmaceutical preparations containing them
US5712280A (en) 1995-04-07 1998-01-27 Schering Corporation Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
FR2738245B1 (fr) 1995-08-28 1997-11-21 Sanofi Sa Nouveaux derives de piperidine, procede pour leur obtention et compositions pharmaceutiques les contenant
DE19624668A1 (de) 1996-06-20 1998-02-19 Klinge Co Chem Pharm Fab Verwendung von Pyridylalkan-, Pyridylalken- bzw. Pyridylalkinsäureamiden
DE19624659A1 (de) * 1996-06-20 1998-01-08 Klinge Co Chem Pharm Fab Neue Pyridylalken- und Pyridylalkinsäureamide
US6451816B1 (en) * 1997-06-20 2002-09-17 Klinge Pharma Gmbh Use of pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides in the treatment of tumors or for immunosuppression
DE19624704A1 (de) 1996-06-20 1998-01-08 Klinge Co Chem Pharm Fab Neue Pyridylalkansäureamide

Also Published As

Publication number Publication date
DE69715888D1 (de) 2002-10-31
US7241745B2 (en) 2007-07-10
DE19624659A1 (de) 1998-01-08
HK1021974A1 (en) 2000-07-21
HU225715B1 (en) 2007-07-30
AU3262597A (en) 1998-01-07
IL127352A (en) 2003-10-31
JP4225572B2 (ja) 2009-02-18
CA2257448A1 (en) 1997-12-24
PT923570E (pt) 2002-12-31
US20030162972A1 (en) 2003-08-28
RU2200734C2 (ru) 2003-03-20
CZ291791B6 (cs) 2003-05-14
CN1546472A (zh) 2004-11-17
DE69715888T2 (de) 2003-07-31
JP2000516913A (ja) 2000-12-19
EP0923570A1 (en) 1999-06-23
CN1152032C (zh) 2004-06-02
CZ409398A3 (cs) 1999-05-12
EP0923570B1 (en) 2002-09-25
US20070219197A1 (en) 2007-09-20
ATE224888T1 (de) 2002-10-15
HUP9903766A2 (en) 2000-09-28
WO1997048696A1 (en) 1997-12-24
BR9709823A (pt) 1999-08-10
TR199802651T2 (xx) 1999-04-21
BR9709823B1 (pt) 2013-09-17
IL127352A0 (en) 1999-10-28
US20070142377A1 (en) 2007-06-21
HUP9903766A3 (en) 2000-12-28
AU736206B2 (en) 2001-07-26
ES2179351T3 (es) 2003-01-16
CN1228777A (zh) 1999-09-15
ZA975437B (en) 1998-02-10
CA2257448C (en) 2008-08-19

Similar Documents

Publication Publication Date Title
DK0923570T3 (da) Pyridylalken- og pyridylalkynsyreamider som cytostatiske og immunosuppresive midler
DK0934309T3 (da) Nye pyridylalkansyreamider som cytostatiske og immunosuppressive midler
ZA975443B (en) Use of pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides.
DK1044197T3 (da) Piperidinylsubstituerede pyridylalkan-, -alken- og -alkyncarboxamider som cytostatiske midler og immunosuppressive midler
SE9904505D0 (sv) Novel compounds
EE200000320A (et) Uudsed ühendid
SE9704544D0 (sv) Novel compounds
NZ511927A (en) Phenylglycine derivatives
TR200200068T2 (tr) Nematisital triflüorobütenler
DK0891331T3 (da) N-(2-Oxoacetyl- eller sulfonyl)pyrrolidin/piperidin-2-carboxylsyrederivater med forbedret multi-lægemiddelresistensaktivitet
ATE296826T1 (de) Pyrazolo(1,5)pyridinderivate
AU5624699A (en) Use of 5ht-6 antagonists
DK0662972T3 (da) 3-, 8-substituerede deuteroporphyrinderivater, farmaceutiske midler indeholdende disse og fremgangsmåder til deres fremstilling
DK1042315T3 (da) Cyklisk imid-substitueret pyridylalkan, alken og alkin carboxamider nyttige som cytostatiske og immunosuppressive midler
ATE188873T1 (de) Tris-platin-komplexe
EE9900450A (et) Tetrahüdropüridoühendid, neid sisaldav ravim ja nende kasutamine
DK0952853T3 (da) Konjugat omfattende et aktivt middel, et polypeptid og en polyether
SE0102058D0 (sv) New Salts II
DK0612763T3 (da) Cykliske angiopeptinderivater, fremgangsmåde til fremstilling heraf og farmaceutiske midler, som indeholder dem
DK0742716T3 (da) Farmaceutisk sammensætning til systemisk transdermal indgivelse med det aktive middel morphin-6-glucuronid
TR200100906T2 (tr) Trombin inhibitörleri olarak benzamid türevleri
SE9803107D0 (sv) Novel Compunds
DE69807200D1 (de) Inklusionskomplexe in waessriger loesung